Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Safe and effective new D2 partial agonist in development at Wyeth-Ayerst

Dec. 9, 1997

Novel valproic acid prodrug reported at scientific meeting

Dec. 9, 1997

New antihyperalgesic agents from Adolor

Dec. 9, 1997

Pfizer improves on NMDA antagonists

Dec. 9, 1997

New muscarinic compound from Wyeth-Ayerst

Dec. 9, 1997

Novo Nordisk develops A1 agonist with neuroprotectant activity

Dec. 9, 1997

Novel therapeutic for anxiety and depression enters phase I

Dec. 8, 1997

Egis prepares new AMPA receptor antagonists

Dec. 8, 1997

Analgesics under evaluation at Ortho

Dec. 8, 1997

Structurally distinct class of 5-HT1B antagonists prepared at SmithKline Beecham

Dec. 8, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...